{"id":4341,"date":"2026-11-16T09:00:00","date_gmt":"2026-11-16T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4341"},"modified":"2026-11-17T20:41:52","modified_gmt":"2026-11-18T00:41:52","slug":"pivot-006-lowers-bladder-tumor-recurrence","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4341","title":{"rendered":"PIVOT 006 Lowers Bladder Tumor Recurrence"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_CG_Oncology_PIVOT006_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4355\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_CG_Oncology_PIVOT006_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_CG_Oncology_PIVOT006_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_CG_Oncology_PIVOT006_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_CG_Oncology_PIVOT006_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_CG_Oncology_PIVOT006_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>CG Oncology<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Phase 3 topline (PIVOT-006)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Intravesical oncolytic immunotherapy<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Cretostimogene grenadenorepvec<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Urothelial tumor cells (oncolysis and immune activation)<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer<\/p>\n<h4>Summary<\/h4>\n<p>CG Oncology reported a Phase 3 recurrence-free-survival hazard ratio of 0.32 for adjuvant intravesical cretostimogene versus surveillance after complete tumor resection in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer. It remains investigational; full results are scheduled for 2 December.<\/p>\n<p>PIVOT-006 randomized 367 patients across about 90 U.S. and Canadian centers. At 17 months median follow-up, the company reported HR 0.32 (95% CI 0.23\u20130.45; p&lt;0.0001), no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations. The control was surveillance after resection. A BLA for this population is planned for Q2 2027; a separate BCG-unresponsive BLA is now planned for March 2027.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>The oncolytic immunotherapy is administered locally, aiming to lyse urothelial tumor cells and stimulate antitumor immunity. <strong>Interpretation A:<\/strong> a large randomized RFS separation could establish an adjuvant option where surveillance is common. The comparator matches a real care pathway and confidence interval excludes modest effects. Counterpoint: recurrence is not progression, cystectomy avoidance or survival, and median follow-up is relatively short.<\/p>\n<p><strong>Interpretation B:<\/strong> frequent cystoscopic detection and post-resection baseline risk could magnify apparent benefit relative to alternative adjuvant approaches. Randomization reduces confounding, but subgroup-specific absolute recurrence and grade distribution await full data. Cross-trial comparison with BCG or other intravesical agents is not valid. Manufacturing reproducibility and tolerability in community practice remain open.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Non-muscle-invasive bladder cancer is confined to the urothelium or lamina propria and frequently recurs after transurethral resection. Cretostimogene grenadenorepvec is an investigational intravesical oncolytic immunotherapy designed to replicate in and lyse tumor cells while recruiting immune attack.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Company topline, not yet full peer-reviewed dataset.<\/li>\n<li>Missing: absolute RFS, duration, progression, grade-specific outcomes, complete adverse-event tables and FDA review feedback.<\/li>\n<li>Upgrade: confirmed durable RFS with low progression and reproducible safety; downgrade: waning benefit or high-grade recurrence imbalance.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The randomized result is a strong clinical signal in a defined bladder-cancer setting, without establishing superiority to other active intravesical regimens.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: positive. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CG Oncology reported a Phase 3 recurrence-free-survival hazard ratio of 0.32 for adjuvant intravesical cretostimogene versus surveillance after complete tumor resection in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer. It remains investigational; full results&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4355,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[661,1498,1499],"class_list":["post-4341","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-bladder-cancer","tag-cg-oncology","tag-cretostimogene"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4341"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4341\/revisions"}],"predecessor-version":[{"id":4357,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4341\/revisions\/4357"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4355"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}